Overview Financials News + Filings Key Docs Ownership Insiders
|
|
Orchestra BioMed Holdings, Inc.
|
|
| Income Statement |
|
|
|
| Standardized | As Reported |
Annual | Quarterly | TTM |
|
| In millions, except per share items | Jun-30-23 | Mar-31-23 | Dec-31-22 | Sep-30-22 | Jun-30-22 | Mar-31-22 | Dec-31-21 | Sep-30-21 |
| | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | 10-Q |
| Total revenues | 0.9 | 1.2 | 0.0 | 0.0 | 0.4 | 0.9 | 0.0 | 0.0 |
| Revenue growth | 128.2% | 34.4% | | | | | | |
| Cost of goods sold | 0.1 | 0.0 | 0.0 | 0.0 | 0.1 | 0.0 | 0.0 | 0.0 |
| Gross profit | 0.9 | 1.1 | 0.0 | 0.0 | 0.3 | 0.8 | 0.0 | 0.0 |
| Gross margin | 94.1% | 96.2% | | | 85.0% | 95.2% | | |
| Selling, general and administrative [+] | 5.3 | 4.4 | 0.8 | 0.8 | 2.9 | 2.5 | 0.1 | 0.1 |
| General and administrative | | | 0.8 | 0.8 | | | 0.1 | 0.1 |
| Research and development | 8.5 | 8.3 | | | 5.0 | 3.5 | | |
| Other operating expenses | | | 0.0 | 0.0 | | | 0.0 | 0.0 |
| EBITDA [+] | -12.9 | -11.5 | | | -7.6 | -5.1 | | |
| EBITDA growth | 69.9% | 125.9% | 852.5% | 761.3% | 7773.9% | 4437.8% | | 37.6% |
| EBITDA margin | -1408.0% | -985.7% | | | -1891.3% | -586.6% | | |
| Depreciation and amortization | 0.1 | 0.1 | | | 0.1 | 0.0 | | |
| EBIT [+] | -13.0 | -11.5 | -0.9 | -0.8 | -7.6 | -5.1 | -0.1 | -0.1 |
| EBIT growth | 69.7% | 125.1% | 852.5% | 761.3% | 7825.8% | 4480.7% | | 37.6% |
| EBIT margin | -1416.0% | -991.8% | | | -1903.7% | -592.1% | | |
| Interest income, net [+] | 0.9 | 0.9 | 0.3 | | -0.2 | -0.2 | 0.0 | |
| Interest expense | 0.5 | 0.4 | | | 0.2 | 0.2 | | |
| Interest income | 0.9 | 0.9 | 0.3 | | | | 0.0 | |
| Other income (expense), net [+] | 0.4 | 0.1 | -0.3 | 0.1 | 0.0 | -0.4 | 0.0 | 0.0 |
| Gain (loss) on investments | 0.0 | 0.0 | | | 1.7 | -0.2 | | |
| Gain (loss) on debt retirement | | | | | -0.7 | | | |
| Change in fair value of warrants | | -0.3 | | | -1.0 | -0.1 | | |
| Pre-tax income | -12.0 | -10.9 | -0.9 | -0.7 | -7.8 | -5.7 | -0.1 | -0.1 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -12.0 | -10.9 | -0.9 | -0.7 | -7.8 | -5.7 | -0.1 | -0.1 |
| Net margin | -1316.5% | -939.9% | | | -1956.9% | -661.5% | | |
| |
| Basic EPS [+] | ($0.35) | ($0.40) | ($0.05) | ($0.05) | ($0.77) | ($0.62) | $0.00 | $0.00 |
| Growth | -55.0% | -36.3% | 1140.2% | 1030.4% | 17043.5% | 11659.0% | | -7.8% |
| Diluted EPS [+] | ($0.35) | ($0.40) | ($0.05) | ($0.05) | ($0.77) | ($0.62) | $0.00 | $0.00 |
| Growth | -55.0% | -36.3% | 1140.2% | 1030.4% | 17043.5% | 11659.0% | | -7.8% |
| |
| Shares outstanding (basic) [+] | 34.6 | 27.6 | 16.4 | 13.7 | 10.1 | 9.2 | 20.5 | 20.5 |
| Growth | 241.4% | 199.7% | -19.7% | -32.9% | -50.4% | -54.9% | | 48.1% |
| Shares outstanding (diluted) [+] | 34.6 | 27.6 | 16.4 | 13.7 | 10.1 | 9.2 | 20.5 | 20.5 |
| Growth | 241.4% | 199.7% | -19.7% | -32.9% | -50.4% | -54.9% | | 48.1% |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|